An observational study in Community-Acquired Pneumonia, sponsored by Centre Hospitalier de Saint-Denis. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Centre Hospitalier de Saint-Denis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Community-Acquired Pneumonia with a site in France — 11 open to participants now, 11 under way, 5 of them phase 3. Community-Acquired Pneumonia · France.
Among the 40 studies in Community-Acquired Pneumonia with a site in France, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 40th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →11 of the 40 studies in Community-Acquired Pneumonia with a site in France are open now. Recruiting first, the newest first:
University Hospital, Caen · Sites in France
University Hospital, Tours · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Biotest · Sites in France, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 650 across 111 observational studies indexed under Community-Acquired Pneumonia.
Median enrollment 327 across the 26 interventional studies, 365 across the 14 observational. Of the 27 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 40 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier de Saint-Denis is the lead sponsor of 46 studies on the registry; 20 are open to participants now.
Centre Hospitalier de Saint-Denis has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
4 of the studies in Community-Acquired Pneumonia with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05903352Phase 3Assistance Publique - Hôpitaux de ParisCustomized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia | 2027-05 |
| NCT06229288Phase 3Nantes University HospitalAmoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward | 2027-05-25 |
| NCT07070284Joan Sabater-RieraESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients | 2026-11-30 |
| NCT06291012University Hospital, MontpellierStopping Pneumonia Antibiotherapy Regimen Early | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Community-Acquired Pneumonia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.
The study population consists of pediatric and adult patients from participating French and Swiss centers who had a positive simplex or multiplex PCR result for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025. Eligible patients must have a documented diagnosis of pneumonia and available clinical data allowing characterization of disease presentation, management, radiological findings, co-infections, and outcomes. Patients who objected to the use of their medical data for research purposes or who did not have pneumonia are excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR
Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.
Time frame: January 2015 to December 2025
Clinical Severity of Chlamydia pneumoniae Pneumonia
Distribution of patients according to outpatient management, hospitalization in a medical ward, admission to intensive care, and in-hospital mortality.
Time frame: From hospital admission through hospital discharge (up to 90 days)
Radiological Characteristics
Chest radiograph and chest computed tomography findings associated with PCR-confirmed Chlamydia pneumoniae pneumonia.
Time frame: Baseline (at the time of pneumonia diagnosis)
Viral Co-Infection Rate
Proportion of patients with concomitant viral infection identified by microbiological testing.
Time frame: Baseline (at the time of PCR testing)
Bacterial Co-Infection Rate
Proportion of patients with concomitant bacterial infection identified by microbiological testing.
Time frame: Baseline (at the time of PCR testing)
Length of Hospital Stay
Duration of hospitalization among admitted patients.
Time frame: From hospital admission through hospital discharge (up to 90 days)
Start is estimated for Jun 2026; primary completion for Sep 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →
Centre Hospitalier de Saint-Denis